Abiologics uses generative AI and high‑throughput chemical protein synthesis to design and produce Synteins™, a new class of programmable, protease‑resistant, immune‑silent biologics.

Alltrna has developed a tRNA platform that utilizes machine learning to design and optimize tRNA molecules for therapeutic applications, specifically targeting diseases caused by genetic mutations that result in premature stop codons. By restoring full-length protein production, Alltrna's approach has the potential to treat thousands of diseases stemming from similar genetic defects.

Ampersand Biomedicines utilizes its proprietary Address, Navigate, Design (AND) Platform to create AND-Body Therapeutics that precisely target disease sites while minimizing effects on healthy tissues. This technology addresses the challenge of off-tissue side effects in drug development by enabling localized drug delivery through optimized localizer targets.

Ampersand Biosciences designs custom Luminex multiplex panels and ELISA kits, validates them for cross‑reactivity, precision and stability, and performs GLP‑compliant testing on samples from mouse, rat, hamster, ferret, canine, human and other models. The company also supplies pre‑validated monoclonal and polyclonal antibodies and recombinant proteins, delivering reproducible biomarker data to pharmaceutical, biotech and academic R&D teams within 2–4 months.

Cellarity utilizes AI and single-cell omics data to develop therapies targeting cellular dysfunction, enabling the creation of medicines for diseases that traditional drug discovery methods cannot address. Their platform integrates biological and chemical insights with multi-omics data to enhance the precision of therapeutic design.

CIBO Technologies offers a cloud‑based software platform that automates the design, enrollment, and management of large‑scale regenerative agriculture and carbon programs. The solution integrates a configurable program engine, the SALUS biogeochemical model, and real‑time computer‑vision and remote‑sensing data to provide field‑level carbon, emissions, and yield estimates, while built‑in incentive‑stacking logic ensures compliance with USDA and private payments. An open API and a nationwide Trusted Advisor Network enable agribusinesses, governments, NGOs, and financial institutions to launch, monitor, and report on sustainable farming initiatives with reduced overhead and verifiable results.

EmpressTX offers the Chemilogics™ platform, which uses human genetic data, AI/ML, and co‑evolutionary algorithms to generate drug‑like small molecules that are naturally encoded in the genome. By predicting and prioritizing millions of chemically diverse candidates and enabling rapid synthetic‑biology production, the platform reduces lead‑identification timelines from years to months, providing pharmaceutical and biotech companies with biologically validated starting points for drug development.

Etiome develops Biostaged Medicines, which aim to intervene in disease progression before it becomes irreversible. Their approach focuses on addressing diseases in earlier stages to prevent debilitating outcomes.

This company develops novel therapeutics by integrating covalent chemistry with artificial intelligence platforms. They build intelligent systems that learn from experimental data to design new medicines. The core focus is creating targeted treatments for diseases driven by specific proteins previously considered undruggable.

This platform uses AI models, validated against live campaign data, to forecast the real-world performance of digital advertisements before launch. It analyzes product details to generate optimized ad copy, imagery, and targeting strategies designed to increase CTR and ROAS. The service allows e-commerce businesses to rapidly test and scale ad creatives based on predictions from AI consumers.

Foghorn Therapeutics uses a structure‑based chemistry platform combined with chemoproteomics and AI‑augmented medicinal chemistry to design selective small‑molecule inhibitors of chromatin‑regulating proteins such as bromodomains, methyltransferases, and demethylases. The company advances these compounds through preclinical validation to IND‑ready candidates, providing epigenetic drug assets to pharmaceutical, biotech, and academic partners.

Generate Biomedicines utilizes generative biology and machine learning to design and produce novel therapeutic proteins, including antibodies and enzymes, with high precision and efficiency. The platform addresses the limitations of traditional drug discovery by enabling on-demand generation of medicines tailored to specific therapeutic functions, significantly accelerating the development process.

Harbinger Health develops a two-tier blood testing model that detects early-stage cancer by identifying biological markers present before tumor formation. This approach addresses the limitations of current cancer detection methods, making early screening accessible and affordable for all individuals.

Indigo provides biological products and flexible sustainability programs that enhance farm profitability while reducing greenhouse gas emissions and conserving water. Their solutions empower farmers and agribusinesses to implement sustainable practices that improve soil health and resilience in agricultural operations.

Invaio Sciences develops precision biotechnologies, including its proprietary Trecise™ application technology, to create biological crop protection solutions that reduce reliance on traditional chemical pesticides. The company addresses crop yield loss due to pests and diseases by providing farmers with sustainable alternatives that enhance environmental health and biodiversity.

Metaphore Biotechnologies utilizes its MIMiC platform, which combines machine learning with molecular mimicry, to design therapeutics that enhance function, specificity, and selectivity for challenging drug targets. The company aims to create transformative treatments that outperform existing drugs, improving patient outcomes in areas like obesity management.

Mirai Bio offers end-to-end development capabilities for biopharmaceuticals, utilizing advanced bioprocessing techniques to streamline product development. The company addresses inefficiencies in the drug development pipeline, enabling faster time-to-market and reduced costs for biotech firms.

The company provides a cell‑free mRNA platform that designs, synthesizes, and formulates therapeutic and vaccine candidates using in‑vitro transcription and proprietary lipid‑nanoparticle delivery. Its automated design suite and continuous‑flow bioprocessing compress development cycles from months to days and enable rapid scale‑up for global distribution. The platform serves pharmaceutical and biotechnology firms seeking accelerated mRNA‑based medicines.

ProFound Therapeutics is utilizing high-throughput biological assessment and novel technologies to identify and analyze a vast array of previously undiscovered proteins encoded by the human genome. This expanded understanding of the human proteome enables the development of new therapeutic interventions for a wide range of diseases.

The startup utilizes its proprietary Decoding Evolutionary Logic of Variant Ensembles (DELVE)™ platform to systematically identify and evaluate viral proteins, enabling the development of programmable medicines. This approach addresses the challenge of precisely regulating human physiology in patients affected by viral diseases.

Quotient Therapeutics utilizes a Somatic Genomics platform to unlock the therapeutic potential of the vast genetic diversity within human cells, enabling the discovery of novel drug candidates. This approach addresses the limitations of traditional genomics by providing insights that lead to targeted treatments for a range of diseases.

RingTherapeutics creates small‑molecule drugs that selectively inhibit Ring finger proteins, a novel intracellular target class involved in immune regulation. Their platform combines structure‑based design, high‑throughput screening, and pharmacokinetic optimization to produce oral therapies with improved safety and efficacy for autoimmune and inflammatory diseases.

ValoHealth uses AI to analyze large-scale human biological data, uncover causal disease mechanisms, and prioritize novel therapeutic targets. Its closed‑loop chemistry platform then rapidly designs, predicts, and synthesizes small‑molecule candidates, integrating biology, chemistry, and engineering in a collaborative network that accelerates early‑stage drug discovery for pharma, biotech, and academic partners.

Vesalius Therapeutics employs a proprietary platform that utilizes patient-derived, cell-based experimental models and advanced data analytics to identify novel drug targets for complex diseases like heart failure and type II diabetes. By recognizing distinct clinical patterns linked to genetic variations, the company aims to develop targeted therapies that address the multifaceted nature of these prevalent illnesses.